Delcath Systems, Inc. (DCTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCTH Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for DCTH is -0.8 -- better than merely 5.3% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 11.2 for DELCATH SYSTEMS INC; that's greater than it is for 92.5% of US stocks.
- Revenue growth over the past 12 months for DELCATH SYSTEMS INC comes in at 114.49%, a number that bests 93.82% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to DELCATH SYSTEMS INC, a group of peers worth examining would be NWBO, CLXT, API, SDGR, and PDFS.
- DCTH's SEC filings can be seen here. And to visit DELCATH SYSTEMS INC's official web site, go to delcath.com.
DCTH Valuation Summary
- DCTH's EV/EBIT ratio is -1.4; this is 121.37% lower than that of the median Healthcare stock.
- DCTH's price/sales ratio has moved up 8 over the prior 59 months.
Below are key valuation metrics over time for DCTH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCTH | 2023-03-17 | 9.0 | -7.2 | -1.2 | -1.4 |
| DCTH | 2023-03-16 | 9.3 | -7.4 | -1.2 | -1.4 |
| DCTH | 2023-03-15 | 9.3 | -7.4 | -1.2 | -1.4 |
| DCTH | 2023-03-14 | 9.6 | -7.7 | -1.3 | -1.5 |
| DCTH | 2023-03-13 | 9.3 | -7.5 | -1.2 | -1.4 |
| DCTH | 2023-03-10 | 9.7 | -7.7 | -1.3 | -1.5 |
DCTH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCTH has a Quality Grade of D, ranking ahead of 7.37% of graded US stocks.
- DCTH's asset turnover comes in at 0.07 -- ranking 160th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows DCTH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.070 | 0.627 | 39.890 |
| 2021-03-31 | 0.067 | 0.613 | 14.650 |
| 2020-12-31 | 0.081 | 0.611 | 9.684 |
| 2020-09-30 | 0.109 | 0.569 | 1.033 |
| 2020-06-30 | 0.099 | 0.556 | 0.617 |
| 2020-03-31 | 0.132 | 0.563 | 0.458 |
DCTH Price Target
For more insight on analysts targets of DCTH, see our DCTH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.75 | Average Broker Recommendation | 1.25 (Strong Buy) |
DCTH Stock Price Chart Interactive Chart >
DCTH Price/Volume Stats
| Current price | $4.46 | 52-week high | $6.82 |
| Prev. close | $4.40 | 52-week low | $2.34 |
| Day low | $4.30 | Volume | 12,341 |
| Day high | $4.49 | Avg. volume | 28,193 |
| 50-day MA | $4.35 | Dividend yield | N/A |
| 200-day MA | $3.80 | Market Cap | 44.81M |
Delcath Systems, Inc. (DCTH) Company Bio
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Latest DCTH News From Around the Web
Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial LaunchDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In a |
Delcath Systems Announces New Drug Application Resubmission for HEPZATO KitDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM). |
Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16. |
Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional RadiologyDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of updated results from the Phase 1b CHOPIN Trial, conducted at Leiden University Medical Center on the use of the Delcath CHEMOSAT® Hepatic Delivery System with Melphalan (CHEMOSAT) in combination with the immune checkpoint inhibitors (ICI) ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with l |
Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4)Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to employment for one individual. |
DCTH Price Returns
| 1-mo | -11.86% |
| 3-mo | 25.28% |
| 6-mo | 23.55% |
| 1-year | -25.67% |
| 3-year | -46.59% |
| 5-year | N/A |
| YTD | 23.89% |
| 2022 | -53.55% |
| 2021 | -56.75% |
| 2020 | -15.67% |
| 2019 | -89.16% |
| 2018 | N/A |
Loading social stream, please wait...